135 related articles for article (PubMed ID: 38305606)
21. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion.
Wong AM; Ding X; Wong AM; Xu M; Zhang L; Leung HH; Chan AW; Song QX; Kwong J; Chan LK; Man M; He M; Chen J; Zhang Z; You W; Lau C; Yu A; Wei Y; Yuan Y; Lai PB; Zhao J; Man K; Yu J; Kahn M; Wong N
J Hepatol; 2022 Aug; 77(2):410-423. PubMed ID: 35351523
[TBL] [Abstract][Full Text] [Related]
22. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
23. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma.
Wang T; Chen B; Meng T; Liu Z; Wu W
Bioengineered; 2021 Dec; 12(1):1555-1575. PubMed ID: 33955820
[TBL] [Abstract][Full Text] [Related]
24. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.
Cai D; Zhao Z; Hu J; Dai X; Zhong G; Gong J; Qi F
Front Surg; 2022; 9():836080. PubMed ID: 35392063
[TBL] [Abstract][Full Text] [Related]
25. Identification of Biomarkers Related to Immune Cell Infiltration in Hepatocellular Carcinoma Using Gene Co-Expression Network.
Zhou W; Chen Y; Luo R; Li Z; Jiang G; Ou X
Pathol Oncol Res; 2021; 27():601693. PubMed ID: 34257558
[TBL] [Abstract][Full Text] [Related]
26. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
28. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.
Lu Y; Wang S; Chi T; Zhao Y; Guo H; Wang H; Feng L
Sci Rep; 2023 Nov; 13(1):18978. PubMed ID: 37923899
[TBL] [Abstract][Full Text] [Related]
29. The Effect of the Histone Chaperones HSPA8 and DEK on Tumor Immunity in Hepatocellular Carcinoma.
Yang C; Shao Y; Wang X; Wang J; Wang P; Huang C; Wang W; Wang J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768989
[TBL] [Abstract][Full Text] [Related]
30. Integrative analysis identifies oxidative stress biomarkers in non-alcoholic fatty liver disease via machine learning and weighted gene co-expression network analysis.
Wang H; Cheng W; Hu P; Ling T; Hu C; Chen Y; Zheng Y; Wang J; Zhao T; You Q
Front Immunol; 2024; 15():1335112. PubMed ID: 38476236
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma.
Pan B; Yang M; Wei X; Li W; Wang K; Yang M; Lu D; Wang R; Cen B; Xu X
Aging (Albany NY); 2021 Jul; 13(14):18620-18644. PubMed ID: 34282055
[TBL] [Abstract][Full Text] [Related]
32. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
33. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients.
Zhang B; Tang B; Gao J; Li J; Kong L; Qin L
J Transl Med; 2020 Sep; 18(1):342. PubMed ID: 32887635
[TBL] [Abstract][Full Text] [Related]
34. Potential targets and molecular mechanism of miR-331-3p in hepatocellular carcinoma identified by weighted gene coexpression network analysis.
Chi Q; Geng X; Xu K; Wang C; Zhao H
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32537629
[TBL] [Abstract][Full Text] [Related]
35. Screening for aberrantly methylated and differentially expressed genes in nonalcoholic fatty liver disease of hepatocellular carcinoma patients with cirrhosis.
Zhang G; Hou Y
World J Surg Oncol; 2022 Nov; 20(1):364. PubMed ID: 36397165
[TBL] [Abstract][Full Text] [Related]
36. A three-gene signature reveals changes in the tumor immune microenvironment in the progression from NAFLD to HCC.
Liu L; Tang H; Wang K; Liu J; Luo N; Jin G
Sci Rep; 2023 Dec; 13(1):22295. PubMed ID: 38102321
[TBL] [Abstract][Full Text] [Related]
37. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
38. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma.
Su Q; Li W; Zhang X; Wu R; Zheng K; Zhou T; Dong Y; He Y; Wang D; Ran J
Curr Pharm Biotechnol; 2023; 24(8):1035-1058. PubMed ID: 35762549
[TBL] [Abstract][Full Text] [Related]
39. Identification of special key genes for alcohol-related hepatocellular carcinoma through bioinformatic analysis.
Zhang X; Kang C; Li N; Liu X; Zhang J; Gao F; Dai L
PeerJ; 2019; 7():e6375. PubMed ID: 30755830
[TBL] [Abstract][Full Text] [Related]
40. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer.
Sun L; Lin Y; Wang G; Zhang L; Hu L; Lu Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33439969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
